AIDS Rates in the US, 1996

Publication
Article
OncologyONCOLOGY Vol 11 No 9
Volume 11
Issue 9

The map shown in Figure 1 provides the annual rates of acquired immunodeficiency syndrome (AIDS) per 100,000 population, by state of residence from January through December 1996. Table 1 lists the metropolitan areas with the 50

The map shown in Figure 1 providesthe annual rates of acquired immunodeficiency syndrome (AIDS) per 100,000population, by state of residence from January through December 1996. Table1 lists the metropolitan areas with the 50 highest annual rates ofAIDS per 100,000 population.

More detailed information about AIDS cases is provided in the HIV/AIDSSurveillance Report, single copies of which are available from theCDC National AIDS Clearinghouse, PO Box 6003, Rockville, MD 20849-6003;telephone, 800-458-5231 or 301-217-0023. Internet users can view an electroniccopy of the report by accessing CDC's World Wide Web home page (http://www.cdc.gov),then selecting "Publications & Products."

Additional information abstracted from AIDS cases reported in the UnitedStates through 1995 is available from the AIDS Public Information DataSet, computer software designed for use with an MS-DOS-based microcomputer.The software can be downloaded from the World Wide Web site http://www.cdc.gov/nchstp/hiv-aids/software.htm. Copies are available from the CDC National AIDS Clearinghouseby requesting inventory number D206.

Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content